Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease

Dicerna Pharmaceuticals Inc DRNA has announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0, and 6.0 mg/kg) of its Phase 1 trial of belcesiran.

  • The GalXC RNAi therapeutic is in development for alpha-1 antitrypsin deficiency-associated liver disease (AATLD), a rare genetic condition that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. 
  • The primary treatment evaluation period for the final dose cohort (12.0 mg/kg) is ongoing.
  • Mean maximum serum AAT reductions from baseline achieved for doses greater than 0.1 mg/kg were: 50% (1.0 mg/kg), 69% (3.0 mg/kg) and 80% (6.0 mg/kg).
  • In the four subjects receiving 6.0 mg/kg, maximum AAT reductions of 91%, 87%, 79%, and 62% were observed. The latter participant experienced a concomitant skin infection (unrelated to belcesiran) and markedly elevated C-reactive protein levels (a measure of inflammation).
  • There were no serious adverse events reported. 
  • Three moderate treatment-emergent adverse events were reported, though unrelated to belcesiran, the Company said.
  • No clinically significant changes in lung function or laboratory tests were reported.
  • Price Action: DRNA shares are down 5.51% at $37.78 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsLiver DiseasePhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!